Omeros Corporation confirms OMS721 phase 3 development plan with EMA
Omeros announced it has received scientific advice from the EMA in connection with the company's OMS721 Phase 3 program. Based on EMA advice, Omeros plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and EU for treatment of aHUS. July 28, 2016